QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe Stephenson who wrote (70)	2/2/1997 1:45:00 PM
From: Donald Gravenor	of 1321

Really a reply to Antal; Nesbitt Burns (the broker division of the Bank of Montreal) rates this stock highly more because of the BPD product for macular degeneration \, rather than for its cancer drugs. I'm an oncologist, and I must say that in North America, most esophageal and lung cancers are too far advanced to benefit from what seems to be a superficial treatment (eg photofrin). The advantage of BPD is that opthalmologists, whom are almost a dime a dozen in the US (there is probably a glut of catteract surgeons) can now do something useful to restore sight in the elderly (other than caterracts). This will increase the use of the QLT drug, with a bit of help from demographics. That's about it. DG

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next